期刊
BRITISH JOURNAL OF CANCER
卷 104, 期 2, 页码 241-247出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6606029
关键词
thyroid atrophy; hypothyroidism; sunitinib; renal cell carcinoma
类别
资金
- Grants-in-Aid for Scientific Research [23659760, 23592320] Funding Source: KAKEN
BACKGROUND: To elucidate the incidence and mechanisms of sunitinib-induced thyroid atrophy, we investigated serial volumetric and functional changes, and evaluated histological changes of the thyroid gland in metastatic renal cell carcinoma patients who received sunitinib. METHODS: Thyroid volume (by computed tomography volumetry) and thyroid function were measured at baseline, during the treatment, and at post-treatment periods. Histological evaluation of the thyroid gland was performed in four autopsied patients. RESULTS: The median reduction rate in thyroid volume at last evaluation during sunitinib treatment was 30% in all 17 patients. The incidence of hypothyroidism during sunitinib treatment was significantly higher in the high reduction rate group (n - 8; more than 50% reduction in volume) than in the low reduction rate group (n 9; less than 50% reduction in volume). Half of the patients in the high reduction rate group exhibited a transient thyroid-stimulating hormone suppression, suggesting thyrotoxicosis during sunitinib treatment. Histological evaluation demonstrated atrophy of thyroid follicles and degeneration of follicular epithelial cells without critical diminution of vascular volume in the thyroid gland. CONCLUSION: Thyroid atrophy is frequently observed following sunitinib treatment and may be brought about by sunitinib-induced thyrotoxicosis or the direct effects of sunitinib that lead to degeneration of thyroid follicular cells. British Journal of Cancer (2011) 104, 241-247. doi: 10.1038/sj.bjc.6606029 www.bjcancer.com Published online 14 December 2010 (C) 2011 Cancer Research UK
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据